Surrozen, Inc.

NASDAQ:SRZN

Biotechnology

Healthcare
$31.74 -4.74%

-$1.14 today

Market cap
$237.33M
Beta
0.51
P/E (TTM)
-0.7
EPS (TTM)
-$31.29
52W Low $8.00High $35.00

Volume 0.31M

Average 0.11M

SRZN Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Surrozen, Inc.NASDAQ: SRZN

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow declines year over year

Q1 FY2026 financing cash flow of $30.28M fell 60.4% year over year, behind the -57.9% change in trailing-twelve-month financing cash flow. Sequentially, it rose 119.7% from the prior quarter.

Context

  • Financing cash flow amounted to 2446.1% of revenue in FY2025, up 2294.3 pp from a year earlier.
  • Financing cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -60.4% toward the trailing-twelve-month pace of -57.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$30.28M+119.7% QoQ
Last fiscal yearDec 2025
$85.05M+425.8% YoY
LTMMar 2026
$38.95M-57.9% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-60.4%——
1 year+425.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
85.05M USD
Year-over-year change
+425.8%
4-year CAGR
-9.1%

Financing Cash Flow vs competitors

How SRZN compares with its peers on the latest reported figures

  • SRZN's LTM Mar 2026 financing cash flow of $38.95M is the 3rd largest of the 8 companies compared; the peer median is $32.01M.
  • Its year-over-year change of -57.9% is the 6th highest of 7, against a peer median of +164.4%.
  • Financing cash flow amounts to 519.7% of revenue for SRZN, versus a peer median of 77.6%.
SRZN Competitors Peer median
Financing Cash Flow for SRZN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMMXImmix Biopharma, Inc.LTM Mar 2026$107.35M —+221.5%—
IRDOpus Genetics, Inc.LTM Mar 2026$57.15M +156.6%+136.4%477.0%
SRZNSurrozen, Inc.LTM Mar 2026$38.95M -57.9%—519.7%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$35.04M +172.3%+87.5%—
AGENAgenus Inc.LTM Mar 2026$32.01M -71.3%+8.6%25.8%
GLSIGreenwich LifeSciences, Inc.LTM Mar 2026$20.54M +350.1%——
SEERSeer, Inc.LTM Mar 2026$11.67M -10.2%—77.6%
TILInstil Bio, Inc.LTM Mar 2026$7.06M +255.3%-53.4%—
Peer median (excluding SRZN) $32.01M+164.4%+87.5%77.6%

Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(54.65M)(36M)(43.04M)(63.56M)(242.03M)
Depreciation & Amortization2.07M1.96M1.91M1.44M537K
Deferred Income Tax00000
Stock-Based Compensation2.32M4.52M4.37M4.11M3.84M
Change in Working Capital(221K)(8.42M)(3.93M)(836K)3.15M
Accounts Receivables0(1.98M)0(502K)2.33M
Inventory00000
Accounts Payables857K(2.04M)(133K)(228K)142K
Other Working Capital(1.08M)(4.4M)(3.8M)(106K)678K
Other Non-Cash Items1.67M(6.2M)325K41.22M204.26M
Operating Cash Flow(48.81M)(44.15M)(40.36M)(17.63M)(30.24M)
Capital Expenditures(1.27M)(728K)(398K)(26K)(128K)
Acquisitions (Net)0(39.04M)000
Purchases of Investments(91.74M)(29.6M)(28.04M)00
Sales of Investments15.3M68.64M80.17M00
Other Investing Activities039.04M000
Investing Cash Flow(77.71M)38.31M51.72M(26K)(128K)
Debt Repayment00000
Common Stock Issued124.22M42K280K16.04M85.05M
Common Stock Repurchased0(2.61M)(4K)00
Dividends Paid00000
Other Financing Activities410K(85K)280K133K0
Financing Cash Flow124.63M(2.57M)276K16.18M85.05M
Effect of Forex Changes00000
Net Change in Cash(1.89M)(8.4M)11.64M(1.48M)54.68M
Free Cash Flow(50.08M)(44.87M)(40.76M)(17.65M)(30.37M)

Surrozen, Inc.

NASDAQ:SRZN

Intrinsic Alpha fair value

Locked

Current Price

$31.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.